Evofem stock surges 27% as Phexxi sales pick up Q/Q, net loss narrows; affirms outlook
Zerbor Evofem Biosciences (NASDAQ:EVFM) stock soared ~31% post market on Aug. 4 after Q2 net loss narrowed and the women health company reaffirmed its FY22 product sales outlook. Q2 net sales of birth control vaginal gel Phexxi grew +42% Q/Q to $6M. The company said the increase reflected higher ex-factory sales and lower gross-to-net adjustments … Read more